Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Centessa Pharmaceuticals plc (NASDAQ:CNTA) has officially announced the appointment of Raphael Deferiere as the company’s new Chief Accounting Officer, effective May 27, 2025. This appointment also designates Deferiere as the principal accounting officer of the company. The announcement was made in a filing with the Securities and Exchange Commission on Thursday, May 29, 2025.
Deferiere, who is 46 years old, brings a wealth of experience to the role, having previously served as an Assurance Partner at Ernst & Young, LLP in Boston from July 2017 to May 2025. His extensive background includes various senior roles at Ernst & Young in Philadelphia, Pittsburgh, and Brussels. Deferiere is a licensed Certified Public Accountant and holds a bachelor’s degree in business administration from Universite Libre de Bruxelles, Belgium.
John Crowley, who previously held the role of principal accounting officer, will continue to serve as the Chief Financial Officer and the company’s principal financial officer. The company noted there are no familial relationships between Deferiere and any other director or executive officer at Centessa Pharmaceuticals, and there are no related party transactions that would require disclosure under SEC regulations.
Regarding compensation, Deferiere’s package includes an annual base salary of $400,000 and eligibility for an annual bonus with a target amount equal to 35% of the base salary, which will be prorated for 2025. Additionally, he will receive an option to purchase up to 165,000 of the company’s American Depositary Shares under the company’s Amended and Restated 2021 Stock Option and Incentive Plan. The options will vest over a period of time, contingent upon continued service with the company.
Centessa Pharmaceuticals, headquartered in the United Kingdom (TADAWUL:4280), operates within the pharmaceutical preparations industry and is listed on the Nasdaq Stock Market under the ticker symbol CNTA. The information regarding the executive change is based on the company’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.